Announcements
- ORIC Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Updates
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
- ORIC Pharmaceuticals Presents Preclinical Data on Two Programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences
- ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates
- ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference
- ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
- ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit
More ▼
Key statistics
On Friday, Oric Pharmaceuticals Inc (4TZ:FRA) closed at 7.90, 71.00% above the 52 week low of 4.62 set on May 31, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.05 |
---|---|
High | 8.05 |
Low | 7.90 |
Bid | 7.80 |
Offer | 7.95 |
Previous close | 8.40 |
Average volume | 295.20 |
---|---|
Shares outstanding | 67.42m |
Free float | 60.98m |
P/E (TTM) | -- |
Market cap | 576.46m USD |
EPS (TTM) | -1.81 USD |
Data delayed at least 15 minutes, as of May 24 2024 14:45 BST.
More ▼